H K Aggarwal1, D Jain2, S Pawar1, R K Yadav1. 1. From the Department of Medicine and Division of Nephrology, Pt. B.D. Sharma University of Health Sciences, Rohtak 124001, Haryana, India. 2. From the Department of Medicine and Division of Nephrology, Pt. B.D. Sharma University of Health Sciences, Rohtak 124001, Haryana, India jaindeepakdr@gmail.com.
Abstract
INTRODUCTION: Improved survival of chronic kidney disease (CKD) patients has led to an increased focus on health-related quality of life (HRQoL) for evaluating treatment effectiveness and assessing health outcomes of these patients. OBJECTIVE: To evaluate HRQoL in patients in different stages of CKD and to explore possible correlating and influencing factors. METHODS: Cross-sectional design with 200 patients from India in CKD stages 1-5 assessed for HRQoL through 36-item short-form together with biomarkers. Patients were divided into four groups according to their estimated Glomerular Filtration Rate (eGFR); group A with GFR range > 90 ml/min/1.73 m2, group B with GFR range 30-59 ml/min/1.73 m2, group C with GFR range 15-29 ml/min/1.73 m2 and group D with GFR < 15 ml/min/1.73 m2 RESULTS: HRQoL scores in all dimensions impaired progressively and significantly across renal function levels and CKD stages. A statistically significant decreasing trend in physical composite summary and mental composite summary scores was found in patients from group A to D (P< 0.001). Patients with eGFR < 30 ml/min/1.73 m2, Diabetes Mellitus, Cardio vascular disease (CVD), C-reactive protein (CRP) ≥ 5 mg/l, Hemoglobin ≤ 90 g/l, erythrocyte sedimentation rate ≥ 20 and mean arterial pressure ≥ 100 mm hg had significantly lower scores on all HRQoL dimensions. Among these CRP, reduced GFR and CVD were the most important predictors of impaired HRQoL. CONCLUSION: Considering the worldwide growing prevalence of CKD and increasing importance of HRQoL in chronic diseases, improving our knowledge about HRQoL and its predictors in CKD patients is important. Assessment of HRQoL early in disease course will help to identify high risk patients in whom modifying these factors may help them lead an active and healthy life.
INTRODUCTION: Improved survival of chronic kidney disease (CKD) patients has led to an increased focus on health-related quality of life (HRQoL) for evaluating treatment effectiveness and assessing health outcomes of these patients. OBJECTIVE: To evaluate HRQoL in patients in different stages of CKD and to explore possible correlating and influencing factors. METHODS: Cross-sectional design with 200 patients from India in CKD stages 1-5 assessed for HRQoL through 36-item short-form together with biomarkers. Patients were divided into four groups according to their estimated Glomerular Filtration Rate (eGFR); group A with GFR range > 90 ml/min/1.73 m2, group B with GFR range 30-59 ml/min/1.73 m2, group C with GFR range 15-29 ml/min/1.73 m2 and group D with GFR < 15 ml/min/1.73 m2 RESULTS: HRQoL scores in all dimensions impaired progressively and significantly across renal function levels and CKD stages. A statistically significant decreasing trend in physical composite summary and mental composite summary scores was found in patients from group A to D (P< 0.001). Patients with eGFR < 30 ml/min/1.73 m2, Diabetes Mellitus, Cardio vascular disease (CVD), C-reactive protein (CRP) ≥ 5 mg/l, Hemoglobin ≤ 90 g/l, erythrocyte sedimentation rate ≥ 20 and mean arterial pressure ≥ 100 mm hg had significantly lower scores on all HRQoL dimensions. Among these CRP, reduced GFR and CVD were the most important predictors of impaired HRQoL. CONCLUSION: Considering the worldwide growing prevalence of CKD and increasing importance of HRQoL in chronic diseases, improving our knowledge about HRQoL and its predictors in CKDpatients is important. Assessment of HRQoL early in disease course will help to identify high risk patients in whom modifying these factors may help them lead an active and healthy life.
Authors: Nicholas C Chesnaye; Yvette Meuleman; Esther N M de Rooij; Ellen K Hoogeveen; Friedo W Dekker; Marie Evans; Agneta A Pagels; Fergus J Caskey; Claudia Torino; Gaetana Porto; Maciej Szymczak; Christiane Drechsler; Christoph Wanner; Kitty J Jager Journal: Clin J Am Soc Nephrol Date: 2022-01-24 Impact factor: 8.237
Authors: Marc Evans; Angharad R Morgan; Martin B Whyte; Wasim Hanif; Stephen C Bain; Philip A Kalra; Sarah Davies; Umesh Dashora; Zaheer Yousef; Dipesh C Patel; W David Strain Journal: Drugs Date: 2021-12-21 Impact factor: 9.546
Authors: Mohammed M Alhaji; Jackson Tan; Mas Rwa Hamid; James A Timbuak; Lin Naing; Nik Aa Tuah Journal: Saudi Med J Date: 2018-07 Impact factor: 1.484
Authors: Nga T Q Nguyen; Paul Cockwell; Alexander P Maxwell; Matthew Griffin; Timothy O'Brien; Ciaran O'Neill Journal: PLoS One Date: 2018-11-26 Impact factor: 3.240
Authors: Edward Zimbudzi; Clement Lo; Sanjeeva Ranasinha; Gregory Fulcher; Martin Gallagher; Stephen Jan; Peter G Kerr; Helena J Teede; Kevan R Polkinghorne; Grant Russell; Rowan G Walker; Sophia Zoungas Journal: Health Qual Life Outcomes Date: 2018-11-19 Impact factor: 3.186
Authors: David C Wheeler; June James; Dipesh Patel; Adie Viljoen; Amar Ali; Marc Evans; Kevin Fernando; Debbie Hicks; Nicola Milne; Philip Newland-Jones; John Wilding Journal: Diabetes Ther Date: 2020-09-29 Impact factor: 2.945